The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.
Search Results: Prevention, Detection & Risk (7 results)
Prostate screening with MRI for men with Lynch syndrome or a BRCA1/2, ATM, BRIP1, CHEK2, PALB2, RAD51C/D, TP53, HOXB13, FANCA or NBN mutation
The National Cancer Institute has opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, NBN, TP53, CHEK2, PALB2, RAD51C RAD51D, BRIP1, FANCA or ATM mutation. The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
People at high risk for prostate cancer due to an inherited mutation
This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.
Screening for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
The purpose of this study is to try to find markers of early pancreatic cancer for screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation
Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)
The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + PALB2
|Clinical Trial||Official Title|
|NCT02478892||Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk|
|NCT05608694||MRI Screening in Men at High Risk of Developing Prostate Cancer|
|NCT03568630||Blood Markers of Early Pancreas Cancer|